Skip to main content
Fig. 5 | BMC Medicine

Fig. 5

From: Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors

Fig. 5

Tucidinostat and checkpoint blockade increase CD8+ T cell infiltration and M1 polarization in tumors. Flow cytometric quantification of lymphocytes (CD45+), total T cells (CD45+CD3+), CD4+ T cells (CD45+CD3+CD4+), CD8+ T cells (CD45+CD3+CD8+), Treg cells (CD45+CD3+CD4+CD25+), central memory T cells (CD3+CD4+CD44+CD62L+CD197+), macrophages (CD45+CD11b+F4/80+), M1 macrophages (CD45+CD11b+F4/80+/MHC-II+), and DCs (CD45+CD11b-CD11c+) in tumor parenchyma (a) and tumor drainage lymph nodes (b) from CT26 tumor-bearing mice on day 21 following different treatment groups (vehicle, tucidinostat, aPD-L1, and combination). The error bars indicate mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 by one-way ANOVA. ns not significant, dLNs drainage lymph nodes, CON control group, Tuc tucidinostat, aPD-L1 anti-programmed cell death ligand 1 antibody

Back to article page